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Summary.-Seventy-one patients suffering from acute myeloid leukaemia (AML)
who were already in complete remission and had already received one further course
of cytotoxic drugs as consolidation therapy were randomised to receive maintenance
chemotherapy alone or the same maintenance chemotherapy plus immunotherapy
with BCG and irradiated allogeneic blast cells. The duration of first remission was
slightly, but not significantly, longer in those patients who received immunotherapy.
This was true also for the duration of survival after relapse. Comparison with other
series suggested that the effect of such immunotherapy on duration of survival
after relapse is probably real, but did 'not clearly indicate whether or not any real
difference in the first remission duration existed.
UNTIL 1972, the only clinical trial in
which immunotherapy had beeii claimed
to be beneficial in the treatment of any
form ofmalignant disease in man was that
of Mathe' et al. (1969) in acute lympho-
blastic lettkaemia. However,largei-, thouah
not identical, trials carried out bv the
Medical Research Council'slVorkingParty
on Leukaemia in Childhood (MRC, 1971)
and by the Leukemia Study Group A
(Heyn ct al., 1.975) failed to confirm
Matlie"sfindings.
In 1969, a series of small sttidies was
undertaken to assess the effects of im-
munotherapy on the duration of first
remission, and on the survival, of adult
patients suffering from acute myeloid
leukaemia (AML) wbo were already in
remission and -%i,ho were all receivinu
regular cliemotliei-apy as maintenance
treatment. In these studies, new patients
Nvere allocated alternately to receive, if
they later entered complete remission,
maintenance treatment with chemother-
apy only or with identical chemotherapy
plus immunotherapy (Powles et al., 1973).
All the chemotherapy, both during induc-
tion and d-Liring remission, was adminis-
tered at St. Bartholomew's Hospital,
London (Bart's) but those patients who
were allocated to receive immunotherapy
were in addition seen regularly at the
Roi-al Marsden Hospital, where all the
immunotherapy was administered. By August 1972, these series were all quite
small, but the duration of first remission
and of survival were, overall, somewhat
better in the immunotherapy group than
in the controls. The studies were numbered
1. 2. 3, 4a and 4b, each containing one or
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two dozen patients, and when Studies 2, 3
and 4a, all of which involved a similar
form of immunotherapy, were pooled, the
apparent effects of immunotherapy on
duration of first remission and on
survival were moderately significant
statistically (P<0.05). Although the
immunotherapy was all administered at
the Royal Marsden, this pool of Studies 2,
3 and 4a has come to be known as "the
Bart's trial", and the chemotherapeutic
regime used in Study 3 has come to be
known as "Bart's 3 chemotherapy".
The encouraging preliminary results
from the Bart's trial indicated the need for
a randomised trial duplicating their study
on a larger scale, and we now report the
results of the trial organized by the
Medical Research Council's (MRC) Work-
ing Party on Leukaemia in Adults which
began in January 1973 with this purpose.
For practical reasons, the MRC trial
was confined to Hammersmith Hospital
and Oxford until 1974. In 1974, 6 hospitals
in the Birmingham region joined the trial.
At Manchester Royal Infirmary the re-
search team had already had some
experience with immunotherapy (Freeman
et al., 1973) andwanted to randomise their
patients between immunotherapy alone
and chemotherapy plus immunotherapy to
discover whether chemotherapy during
remission was ofvaluetopatientsreceiving
immunotherapy. The Manchester part of
theMRC study will be reported separately.
At Birmingham, Hammersmith and
Oxford 148 patients presented; 77 ofthese
achieved complete remission (520 %) and 71
of these were randomised between chemo-
therapy and chemotherapy plus immuno-
therapy.
PATIENTS AND METHODS
From 1st January, 1973 to 30th June, 1976,
71 patients who had entered complete remis-
sion were allocated at random to receive
maintenance therapy, either with chemo-
therapy alone (C, 24 patients) or with
immunotherapy as well as the same chemo-
therapy (C+I, 47 patients). The follow-up is
complete to 1st July 1977.
The chemotherapy schedules for induction
and maintenance therapy were identical with
those described by Powles et al. (1973)
except that doxorubicin was occasionally
substituted for daunorubicin, at half the
dosage, to reduce the risk of cardiotoxicity.
For details of the induction chemotherapy
with the 5-day course of daunorubicin and
cytosine arabinoside repeated at 10-day
intervals, and of the monthly maintenance
chemotherapy courses of the same drugs,
alternating with thioguanine and cytosine
arabinoside, see Powles et al. (1973).
The immunotherapy involved the weekly
injection of -109 allogeneic irradiated blast
cells (each patient receiving, as far as possible,
cells from a single donor). The suspensions
were injected intradermally (i.d.) and s.c. at 3
sites on the limbs (the volume being too great
for purely i.d. injection). At a 4th site Glaxo
freeze-dried BCG (,106 organisms) was
injected percutaneously to a depth of 2 mm
through 40 punctures made with a Heaf gun.
This regimen was identical with that used in
Study 3 of the Bart's trial (Powles et al.,
1973). As in that trial, maintenance chemo-
therapy was discontinued after one year;
Group C patients then received no further
treatment until they relapsed, while Group
(C+I) patients continued to receive immuno-
therapy but no chemotherapy. Patients who
relapsed received the same treatment as was
used to induce their first remission, but some
who relapsed within 120 days, or whorelapsed
a second time, then received more intensive
therapy. Patients in Group (C+I) whose
disease entered remission a second time
continued to receive immunotherapy as part
oftheir maintenance therapy.
The MRC trial was designed to duplicate
the Bart's trial in all respects and in the
planning of the trial, and throughout its
duration, close collaboration was maintained
with the late Professor G. Hamilton Fairley
and Dr R. L. Powles to ensure that the details
of every procedure in the MRC trial were as
nearly as possible the same as in the Bart's
trial. Nevertheless, there were some minor
differencesinprocedurebetweenthetwotrials.
These differences were as follows:
(1) In the Bart's trial, the allocation to
maintenance chemotherapy only (C) or to
chemotherapy and immunotherapy (C+I)
was made to alternate patients at the time of
first presentation, before remission had been
induced. In the MRC trial, the allocation was
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made randomly, at the time when the patient
was first recorded as having entered a state of
complete remission. The randomization pro-
cedure was adjusted so that twice as many
patients would be allocated to receive (C+I)
as C.
(2) In the Bart's trial, immunotherapy was
begun "whenever possible, just before com-
plete remission, at a time when the marrow
was hypoplastic" (Powles et al., 1973). This
was possible because the patients had already
been allocated to receive immunotherapy. In
the MRC trial, randomization was deferred
until complete remission was established,
as shown by the regeneration in the
marrow of normal haemopoietic cells as well
as the reduction of blast cells below 5%.
After the first marrow sample considered to
show complete remission, one further "con-
solidation" course ofchemotherapy was given
before starting immunotherapy. Thus, im-
munotherapy was begun 1 to 4 weeks later in
the MRC trial patients than in the Bart's
trial patients.
(3) In the MRC trial, the marrow was
examined on the first day of every monthly
course of maintenance chemotherapy, with
the object of detecting relapse as early as
possible. Blast-cell counts above 5% were
considered to indicate relapse, but to allow for
variation between different sites in the
marrow, and for observer variability, a single
sample of marrow showing 5-10% of blasts
was not accepted as indicating relapse unless
blast cells were present inthe peripheral blood
film at the same time. If they were not, a
second marrow sample was taken 4 weeks
later, and a blast-cell count above 5% was
then accepted as indicating relapse. In the
Bart's trial, marrow examinations were
not made routinely during remission, being
performed only when indicated by the peri-
pheral blood and clinical findings.
(4) In the MRC trial, in accordance with
the practice in earlier trials, patients aged 20
years and over who had undifferentiated
leukaemia were eligible for entry, whereas
in the Bart's trial they were deliberately ex-
cluded, entry being restricted to patients with
leukaemia showing definite myeloid (granulo-
cytic and/or monocytic) differentiation.
(5) Finally, in the Bart's trial, when
patients relapsed, "the initial induction treat-
ment with daunorubicin and cytosine arabi-
noside was repeated whenever possible". In
the MRC trial, participants were encouraged
to do this, but were free to use more intensive
treatment for patients who relapsed within
120 days or for a second time.
COMPLICATIONS OF IMMUNOTHERAPY
In general, immunotherapy was well
tolerated; however, severe reactions oc-
curred in a few cases. The sites ofthe BCG
inoculations were sometimes slow to heal
and, when persistently discharing ulcera-
tion occurred, inoculations of BCG were
discontinued until the ulcers had healed.
In 2 cases in which the BCG inoculation
sites healed normally, the sites ofthe blast-
cell injections became inflamed and ulcera-
ted, the patients became febrile, and BCG
organisms were recovered from the ulcer.
These patients were considered to have
developed systemic BCG disease and were
successfully treated with antituberculosis
drugs. Rarely, patients complained of
generalised muscle aching and weakness
during the 24 h following immunotherapy,
and most patients complained of transient
pain at the inoculation sites.
In 3 immunotherapy patients tempor-
ary iritis was reported, though no explicit
search for this condition was organised.
STATISTICAL METHODS
These are as described by Peto et al.
(1976; 1977) and consist of Kaplan-
Meier life tables and logrank P values*.
For the latter, exact variance calculations
were performed (ibid., Statistical Note 7)
and continuity corrections were not used
(ibid, p. 38).
* Because we were testing a previously published claim thatimmunotherapy helps, we have cited one-tailed
P values when comparing treatments, but otherwise we have cited ordinary P values.
One-tailed P values give the probabilities of observing, by chance alone, the differences we did observe in
favour ofimmunotherapy. Obviously, if chance alone were operating, there would be an equal probability of
observing an equivalent difference in the opposite direction, and the total probability of observing a difference
of the magnitude we did, which is the ordinary P value, is therefore double the one-tailed P value which
we cite when comparing treatments.
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RESULTS
Data for each randomised patient are
listed separately inthe Appendix. We have
examined 3 different measures ofoutcome:
(1) Duration of complete remission (all
71 patients: 24 C, 47 C+I).
(2) Duration of survival from the date
of first relapse (analysed for the 60
patients who relapsed before 1 July
1977: 23 C, 37C+l).
(3) Duration of survival from random-
ization (all 71 patients).
(1) Duration of complete remission
(I.e. time from definite remission to first
relapse or, for 2 patients who died while
still in their first remission, to death.)
There were no significant differences in
the duration of first remission between
patients of different ages or patients from
different centres (Oxford, Hammersmith
or Birmingham region) (Table I). Al-
though the immunotherapy patients fared
slightly better (Fig. 1) this difference was
not statistically significant (Table I)
(whether tested directly or after retrospec-
tive stratification for centre.) "Retrospec-
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tive stratification for centre" (Peto et al.,
1976; 1977) implies that, in making the
overall treatment comparison, patients at
one centre are not assumed to be compar-
able with patients elsewhere.) The ratio of
the relapse rate among immunotherapy
patients to that among the controls was
074, but because the trial is not large, the
95% confidence interval for this ratio is
rather wide (,.'0O45-1-20) and our data are
thus consistent both with no effect what-
soever for immunotherapy and with a
halving of the relapse rate by immuno-
therapy.
(2) Duration of survival from the date of
relapse
The median survial after relapse had
been diagnosed was only 124 days (18
weeks) and it tended to be shorter in the
Birmingham area (14 weeks) than at
Hammersmith and Oxford (22 weeks).
After relapse, the immunotherapy+
chemotherapy patients (Fig. 2) lived some-
what longer (median 22 weeks) than the
chemotherapy only patients (14 weeks).
However, such medians are usually rather
0
a
2 3
TIME SINCE REMISSION
FIG. 1.-Life-table estimate of the probability of survival in complete remission of 71 patients
allocated at random for maintenance treatment by chemotherapy alone (C, 24 patients )
or chemotherapy and immunotherapy (C+I, 47 patients - -- -). (All patients have been
followed up for 18 or more months.) Solid symbols, relapse; open symbols, incomplete follow-up.
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FIG. 2.-Life-table estimate ofthe probability
of survival after the first relapse of 60
patients who relapsed before 1 July
1977. 37 patients were in the group receiv-
ing both chemotherapy and immuno-
therapy ( - - ) and 23 in the group
receiving only chemotherapy ( ). (All
but 3 of these patients have been followed
up for over a year, but 9 more may yet
relapse and thus enter this comparison.)
Solid symbols, death; open symbols, in-
complete follow-up.
unreliable* because medians are derived
from only a single point on the whole
survival curve. It is, therefore, usually
preferable to use a logrank test to see
whether, taking the entire shapes of the
two curves into consideration, the differ-
ences between the two curves can be
plausibly attributed solely to chance.
Unfortunately, as with remission duration,
the results are equivocal. There is no
statistically significant difference in sur-
vival after relapse (chi-square on one
degree of freedom 2, one-tailed P=008)
yet the data are consistent not only with
no effect but also with at least a halving of
the death rate among relapsed patients
(observed death rate ratio-0*68, 95%
confidence interval -0-40-1.15).
(3) Survivalfrom randomization (i.e.)from
the onset of remission)
As might be expected, the relationship
of treatment to overall survival is similar
to that with remission duration (Fig. 3 and
Table III). Again, the data are consistent
both with a halving of the death rate and
with no effect whatever. (The observed
death rate ratio was 067, with 95%
confidence interval -'0O39-1-14.)
DISCUSSION
The present trial was started in 1973,
shortly after an unpublished statistical
analysis ofthe Bart's immunotherapy trial
suggested that the duration of remission
was significantly longer if, during remis-
sion, the patients received weekly im-
munotherapy in addition to monthly
courses of chemotherapy, instead of the
same chemotherapy alone. Analysis of the
Bart's results one year later (Powles et at.,
1973) suggested that, in addition to the
prolongation of the first remission, the
duration of survival after the first relapse
and the overall survival were also superior
in the group of patients who had received
immunotherapy.
Further follow-up of the original Bart's
trial (Powles et al., 1977) has shown that
the statistical significance of the effect on
first remission which they originally re-
ported (Powles et al., 1973) no longer
exists. Now that more complete informa-
tion is available for all their patients, it
appears that the effect reported earlier on
the duration of first remission could have
been a temporary artefact of chance, and
all but one patient in their original
immunotherapy group had relapsed bythe
end of 1976.
In our data, the immunotherapy-
treated group has had slightly longer
durations, both of first remission and of
survival after first relapse. However, both
* For example, although the discrepancy of 8 weeks between these two medians looks promising, consider
the medians we would have obtained if just one extra immunotherapy patient had relapsed. If this hypo-
thetical patient had died 6 months after his relapse, the present medians would be unchanged, but if he had
diedfour months after his relapse the discrepancy between the medians of the two treatment groups would
be reduced to 4 weeks.
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FIG. 3.-Life-table estimate of the probability of survival after randomization of 71 patients in com-
plete remission who received either chemotherapy alone (C, 24 patients ), or chemotherapy
and immunotherapy (C+I, 47 patients --- -). (All patients have been followed up for 18 or more
months.) Solid symbols, death; open symbols, incomplete follow-up.
these differences (and the difference with
respect to total survival) areeasilycompat-
ible with (a) immunotherapy being com-
pletely without benefit, and (b) immuno-
therapy halving the relapse rate, the death
rate among relapsed patients, or both.
A larger trial would have been much
more informative, but this was not achiev-
ed for the reasons already described; but,
it should be remembered, our trial is
larger than any other randomized trial of
immunotherapy for AML yet reported. To
obtain independent confirmation or re-
futation of the original Bart's results, we
must therefore look to other series of
patients. Two questions need answering:
Does immunotherapy prolong first remis-
sion? and does immunotherapy prolong
survival afterrelapse?
First Remission
At a meeting at the National Cancer
Institute (NCI, 1977) in October 1976, it
was intended that all randomized trials of
immunotherapy should be reviewed to-
gether.
Four other randomized AML trials
were presented, in addition to the Bart's
andMRC trials. The South Eastern Cancer
Study Group reported P<0 05 for the
duration of first remission, but this
difference appeared to exist more because
their controls fared unduly badly (median
13 weeks to relapse) than because their
immunotherapy patients (median 25
weeks) fared well, and may, therefore, be
an artefact of chance. However, in all 6
trials (Bart's, MRC, S.E. U.S.A., S.W.
U.S.A., South Wales and Central Sweden)
first remissions were somewhat longer
among immunotherapy patients, although
in 5 of these 6 trials the differences were
not statistically significant. This indicates,
again inconclusively, that immunotherapy
does prolong first remission.
Less reliable evidence may be derived by
comparing what happened to single groups
of AML patients at various different
centres who achieved remission concur-
rently with the patients in the MRC trial.
All other centres participating in the 6th
AML trial during the period of intake to
the present trial used, in one arm or other,
the same chemotherapy and criteria of
9
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remission as in the present trial. All except
Manchester used no immunotherapy and,
among the 40 such patients who achieved
remission, first remissions were actually
slightly longer than among either group in
our randomized trial. Conversely, 10
patients at Manchester received immuno-
therapy as well as this chemotherapy, and
their first remissions were slightly shorter
than in our randomized trial. Finally, 41
patients remitting at Bart's during this
period (after closure oftheir trial) received
various different forms of chemotherapy
and various different forms of immuno-
therapy, and their first remissions were
also slightly shorter than among either
group in our randomized trial. These three
concurrent comparisons are all uncertain,
because the treatments were not allocated
by randomization, but none suggests that
immunotherapy prolongs first remissions.
Survival After Relapse
Here, the 5 other randomized studies
and the 3 concurrent comparisons all
indicate, as was originally suggested by
Freeman et al. (1973) that immunotherapy
does prolong survival after relapse. In all 6
randomized trials (NCI, 1977) survival
after relapsewasbetterforimmunotherapy
patients, and in 3 of these the differences
were apparently statistically significant.
(However, the detailed data from one of
these 3 trials have been tabulated by
Whittaker and Slater (1977) and re-
analysis of the tabulated data indicates
that although a difference certainly exists,
it is not statistically significant.)
In the MRC 6th chemotherapy trial, 28
of the (already mentioned) 40 patients
treated according to the "Bart's 3"
protocol relapsed, and these 28 then died
more quickly after relapse than either of
the two groups in the present randomized
trial. By contrast, both the group of 10
C+1 patients who relapsed at Manchester,
and the group of 31 C+I patients who
presented at Bart's after closure of their
trial and relapsed before 1977, lived longer
after relapse than did either randomized
group in the present trial. This reinforces
the suggestion that immunotherapy can
prolong survival after relapse, but again
the possible biases inherent in such non-
randomized comparisons should be empha-
sized.
Other Reports of the Present Trial
At the NCI review meeting in October
1976 (NCI, 1977) our results to the end of
September 1976 were presented. The
present paper reports our results 9 months
later, when 16 further relapses and deaths
have occurred (6 among C-only patients
and 10 among C+I patients, because two-
thirds of our patients were allocated to
receive C+J). The present uncertain
results are almost identical with the
results presented then. However, at the
MRC annual review meeting, a significant
effect of immunotherapy in prolonging
survival after relapse was reported from
this trial. This was because all 6 of the C-
only events occurred before 1 January
1977, while only 2 ofthe 10C+Ieventsdid
so. In small trials, quite rapid changes can
always occur, and because 19 patients
remain alive (9 in first remission) further
fluctuation is still possible but perhaps
unlikely.
CONCLUSION
It seems probable, though not certain,
that immunotherapy can prolong survival
after relapse, and it is possible that it can
slightly extend first remissions. The mech-
anism in either case remains obscure, and
comparisons with successful immuno-
therapy in experimental animals are not
necessarily relevant. If our "immuno-
therapy" really does have some effect,
elucidation ofits mechanism might lead to
improvement in its efficacy. It is, however,
not yet clear that future efforts to improve
survival in AML should chiefly be directed
to improving immunotherapy, and we
have not included immunotherapy in the
current (7th) MRC AML trial.
Several laboratory tests, including stud-
ies of the immunological responses of the
patients receiving immunotherapy in the
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trial reported here, have been carried out,
and several of the blast-cell preparations
used for immunization proved to be
immunogenically "inert" (personal com-
munication: Dr I. C. M. MacLennan, Dr
D. Gale, Dr R. Harris, Dr G. M. Taylor). It
remains possible, therefore, that other
forms of immunotherapy may be more
effective. In experimental animals im-
munotherapy is effective only when the
number of residual tumour cells is very
small.
Possibly our immunotherapy was begun
too soon or too late to be maximally
effective. The Manchester group have
suggested more intensive consolidation
therapy before randomizing between im-
munotherapy and no other maintenance
treatment, and they are now carrying out
a trial so designed.
The principal physicians entering patients were
Dr Goldman (Hammersmith), Dr Callender (Oxford)
Dr Shinton (Coventry), Dr Giles (Stoke), Dr Pollock
(Birmingham), Dr Stewart (Birmingham QE), Dr
Bagshawe (Charing Cross) and Dr Allan (Wolver-
hampton).
Colleagues in radiotherapy and radiobiology
irradiated the blast cells weekly before injection.
The data were collected by Miss M. Gilham and
analysed by Mr R. Peto and Dr H. Cuckle. Miss M.
Gilham, Mrs D. L. Haysome, Miss A. Spira,
Ms R. Coggins and Ms G. Mead typed proto-
cols and manuscripts.
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Noteaddedinproof.-By 1 November 1977, allpatientshadbeenfollowedfor22 or moremonths,
andonfurtherstatisticalanalysisthe3treatmentchi-squares (retrospectivelystratifiedforcentre)
became 1P53 (first remission), 1-97 (survival after relapse) and 2-61 (overall survival). None of
the explanatory variables listed in the Appendix (no. of courses, sex, age, morphology, centre
or WBC) were significantly related to any measure ofoutcome, nor did retrospective stratifica-
tion for any ofthem materially affect the relationships of treatment with outcome. (However,
patients with only 3, 4 or 5 courses of tratment during the first 12 weeks after diagnosis did
live slightly longer than those with 6, 7 or 8 courses, and the apparent effect of immunotherapy
was somewhat greater among the latter than among the former patients.) Because the Bart's
trial excluded patients with undifferentiated leukaemia, we finally re-analysed our data
excluding our 9 such patients; their prognosis was slightly worse than average, and no
material change in any of our 3 treatment comparisons followed their exclusion.MEDICAL RESEARCH COUNCIL
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